Medifast Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view top-rated stocks.

Wall Street analysts have given Medifast a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medifast wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Medifast.

Medifast, Inc. (NYSE:MED) posted its earnings results on Tuesday, May, 4th. The specialty retailer reported $3.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.72 by $0.74. The specialty retailer had revenue of $340.70 million for the quarter, compared to the consensus estimate of $279.12 million. Medifast had a trailing twelve-month return on equity of 85.97% and a net margin of 11.44%. The business's revenue for the quarter was up 90.9% compared to the same quarter last year.
View Medifast's earnings history.

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 293.8% and is now trading at $277.37.
View which stocks have been most impacted by COVID-19.

Medifast announced a quarterly dividend on Thursday, June 3rd. Shareholders of record on Tuesday, June 22nd will be paid a dividend of $1.42 per share on Friday, August 6th. This represents a $5.68 annualized dividend and a yield of 2.05%. The ex-dividend date is Monday, June 21st.
View Medifast's dividend history.

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 2.10%. Medifast does not yet have a strong track record of dividend growth. The dividend payout ratio of Medifast is 62.14%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 37.77% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

Medifast issued an update on its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided EPS guidance of 12.690-14.140 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.110. The company issued revenue guidance of $1.40 billion-$1.48 billion, compared to the consensus revenue estimate of $1.19 billion.

3 equities research analysts have issued twelve-month price targets for Medifast's stock. Their forecasts range from $265.00 to $400.00. On average, they expect Medifast's stock price to reach $353.33 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price.
View analysts' price targets for Medifast or view top-rated stocks among Wall Street analysts.

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medifast include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.42%), Renaissance Technologies LLC (7.60%), Dimensional Fund Advisors LP (3.24%), Bank of New York Mellon Corp (1.83%), Principal Financial Group Inc. (1.72%) and Principal Financial Group Inc. (1.72%). Company insiders that own Medifast stock include Daniel R Chard, Jeffrey J Brown, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Schroder Investment Management Group, Ameriprise Financial Inc., Dimensional Fund Advisors LP, Landscape Capital Management L.L.C., Victory Capital Management Inc., and Man Group plc. Company insiders that have sold Medifast company stock in the last year include Daniel R Chard, Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast or view top insider-selling stocks.

MED stock was bought by a variety of institutional investors in the last quarter, including Prudential Financial Inc., BlackRock Inc., Millennium Management LLC, Castleark Management LLC, Lombard Odier Asset Management USA Corp, Squarepoint Ops LLC, Geode Capital Management LLC, and BI Asset Management Fondsmaeglerselskab A S.
View insider buying and selling activity for Medifast or or view top insider-buying stocks.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $277.37.

Medifast has a market capitalization of $3.26 billion and generates $934.84 million in revenue each year. The specialty retailer earns $102.86 million in net income (profit) each year or $9.14 on an earnings per share basis.

Medifast employs 713 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]